|
Description of Business and Summary of Significant Accounting Policies (Details) (USD $)
|
0 Months Ended |
3 Months Ended |
6 Months Ended |
|
6 Months Ended |
3 Months Ended |
6 Months Ended |
0 Months Ended |
|
|
6 Months Ended |
|
6 Months Ended |
3 Months Ended |
6 Months Ended |
3 Months Ended |
6 Months Ended |
3 Months Ended |
6 Months Ended |
3 Months Ended |
12 Months Ended |
|
Jul. 12, 2012
|
Nov. 22, 2011
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
ClinicalandScientificAdvisor
|
Sep. 30, 2012
|
Mar. 31, 2013
|
Sep. 30, 2013
Range $2.90 to $6.00 [Member]
|
Sep. 30, 2013
Range $6.25 to $11.70 [Member]
|
Sep. 30, 2013
Range $17.80 to $28.10 [Member]
|
Sep. 30, 2013
Range $34.20 to $61.80 [Member]
|
Sep. 30, 2013
Range $89.52 to 174.00 [Member]
|
Sep. 30, 2013
Range $2.90 to $174.00 [Member]
|
Sep. 30, 2013
Stock Options [Member]
|
Sep. 30, 2012
Stock Options [Member]
|
Sep. 30, 2013
Stock Options [Member]
|
Sep. 30, 2013
Restricted Stock Units (RSUs) [Member]
|
Mar. 21, 2013
Sequel Power [Member]
|
Jan. 14, 2011
Sequel Power [Member]
|
Sep. 30, 2013
Minimum [Member]
|
Sep. 30, 2013
Minimum [Member]
Patents [Member]
|
Sep. 30, 2013
Minimum [Member]
Trademarks [Member]
|
Sep. 30, 2013
Maximum [Member]
|
Sep. 30, 2013
Maximum [Member]
Patents [Member]
|
Sep. 30, 2013
Maximum [Member]
Trademarks [Member]
|
Sep. 30, 2013
Revenue [Member]
Life Technologies [Member]
|
Sep. 30, 2013
Revenue [Member]
Life Technologies [Member]
|
Sep. 30, 2013
Revenue [Member]
Everyday Health [Member]
|
Sep. 30, 2012
Revenue [Member]
Everyday Health [Member]
|
Sep. 30, 2013
Revenue [Member]
Everyday Health [Member]
|
Sep. 30, 2012
Revenue [Member]
Everyday Health [Member]
|
Sep. 30, 2012
Revenue [Member]
Sequel Power [Member]
|
Sep. 30, 2012
Revenue [Member]
Sequel Power [Member]
|
Sep. 30, 2013
Accounts Receivable [Member]
Life Technologies [Member]
|
Sep. 30, 2013
Nanolayer Deposition Technology [Member]
|
Mar. 31, 2013
Nanolayer Deposition Technology [Member]
|
| Description of Business and Summary of Significant Accounting Policies [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net loss |
|
|
$ 563,000
|
|
$ 1,284,000
|
$ 1,360,000
|
$ 1,963,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net cash used in operating activities |
|
|
|
|
|
1,237,000
|
1,708,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of clinical and scientific advisors |
|
|
|
|
|
75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash equivalents |
|
|
2,791,000
|
|
|
2,791,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from the sale of NLD patents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
365,000
|
3,750,000
|
| Commission expenses related to sale of patents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
89,000
|
|
| Additional expenses recognized related to sale of patents |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,000
|
|
| Net Revenue from sale of two patent lots |
|
|
267,000
|
20,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
267,000
|
|
| Discontinued operation, foreign currency translation |
|
|
|
|
|
142,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration Risk [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Concentration risk (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60%
|
96.00%
|
0.00%
|
67.70%
|
3.80%
|
50.00%
|
33.30%
|
50.00%
|
100.00%
|
|
|
| Promissory Note [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business acquisition effective date |
Jul. 12,
2012
|
|
|
|
|
Jul. 12,
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Promissory note assumed |
500,000
|
|
500,000
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note receivable used as consideration for CollabRx acquisition |
|
300,000
|
|
|
|
0
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest rate on promissory note (in hundredths) |
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Promissory note maturity date |
|
Nov. 15,
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment in convertible promissory note |
|
|
362,000
|
|
|
362,000
|
|
345,000
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accrued interest on note receivable |
|
|
62,000
|
|
|
62,000
|
|
45,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Class of Warrant or Right [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding to purchase shares of common stock (in shares) |
|
|
285,454
|
|
|
285,454
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 30.00
|
|
|
$ 495.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment warrants expiration date range start |
|
|
|
|
|
Feb.
01,
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment warrants expiration date range end |
|
|
|
|
|
Sep.
01,
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reclassification from additional paid in capital to beginning accumulated deficit |
|
|
346,000
|
|
|
346,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reclassification from additional paid in capital to common stock warrant liability |
|
|
502,000
|
|
|
502,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of warrants |
|
|
0
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non cash gains on warrants |
|
|
|
|
|
10,000
|
3,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Equity Method Investments [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity investment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ownership interest (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants cancelled (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
44,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
92,888
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investment in Unconsolidated Affiliate [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated useful life of the underlying intangibles |
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 years
|
3 years
|
|
10 years
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
| Change in the fair value of warrants [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance at the beginning of the period |
|
|
|
10,000
|
|
10,000
|
19,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value recorded in earnings |
|
|
|
|
|
(10,000)
|
(3,000)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance at the end of the period |
|
|
0
|
|
16,000
|
0
|
16,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Useful life |
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 years
|
3 years
|
|
10 years
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of intangible assets |
|
|
|
|
|
105,000
|
20,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-Based Compensation [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vesting period of equity awards |
|
|
|
|
|
4 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock options expiry period |
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price of shares to fair market value (in hundredths) |
|
|
|
|
|
85.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total stock-based compensation expense related to stock options and restricted stock units |
|
|
|
|
|
175,000
|
312,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total compensation expense related to non-vested stock options and RSUs not yet recognized |
|
|
551,000
|
|
|
551,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Valuation assumptions to estimate the fair value of options and ESPP [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected life (years) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6 years
|
6 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Volatility (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152.40%
|
157.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk-free interest rate (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.55%
|
0.62%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dividend yield (in hundredths) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock option and warrant activity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Beginning outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
263,876
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29,499
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expected (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
293,375
|
|
293,375
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending vested and expected to vest (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
293,096
|
|
293,096
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending exercisable (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
177,057
|
|
177,057
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted Average Exercise Price [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Beginning outstanding (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10.23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3.94
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expired (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending outstanding (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9.60
|
|
$ 9.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending vested and expected to vest (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9.59
|
|
$ 9.59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending exercisable (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 13.32
|
|
$ 13.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted Average Remaining Contractual Term [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7 years 4 months 2 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending vested and expected to vest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7 years 4 months 2 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6 years 2 months 1 day
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate Intrinsic Value [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,448,000
|
|
27,448,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending vested and expected to vest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,435,000
|
|
27,435,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ending exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,648,000
|
|
20,648,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total unrecognized compensation cost related to outstanding options and warrants |
|
|
282,000
|
|
|
282,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Period of recognition of total unrecognized compensation cost related to options outstanding |
|
|
|
|
|
3 years
|
1 year 8 months 26 days
|
|
|
|
|
|
|
|
|
|
|
|
1 year 8 months 26 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of Shares [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance, March 31, 2012 (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
183,904
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vested (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(34,750)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance, Dec. 31, 2012 (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
149,154
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted Average Grant Date Fair Value [Abstract] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance March 31, 2013 (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.67
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vested (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance, June 30, 2013 (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total unrecognized compensation cost related to outstanding RSUs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 269,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Period of recognition of total unrecognized compensation cost |
|
|
|
|
|
3 years
|
1 year 8 months 26 days
|
|
|
|
|
|
|
|
|
|
|
|
1 year 8 months 26 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Range of Exercise Prices, Lower Range Limit (in dollars per share) |
|
|
|
|
|
|
|
|
|
$ 2.90
|
$ 6.25
|
$ 17.80
|
$ 34.20
|
$ 89.52
|
$ 2.90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Range of Exercise Prices, Upper Range Limit (in dollars per share) |
|
|
|
|
|
|
|
|
|
$ 6.00
|
$ 11.70
|
$ 28.10
|
$ 61.80
|
$ 174.00
|
$ 174.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number Outstanding (in shares) |
|
|
|
|
|
|
|
|
|
193,828
|
45,358
|
39,244
|
13,998
|
947
|
293,375
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted Average Remaining Contractual Term |
|
|
|
|
|
|
|
|
|
8 years 11 months 23 days
|
5 years 1 month 20 days
|
3 years 11 months 19 days
|
1 year 8 months 5 days
|
11 months 5 days
|
7 years 4 months 2 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
|
|
|
|
|
$ 3.83
|
$ 11.50
|
$ 21.63
|
$ 43.95
|
$ 93.95
|
$ 9.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number Exercisable (in shares) |
|
|
|
|
|
|
|
|
|
77,579
|
45,358
|
39,244
|
13,998
|
878
|
177,057
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted Average Exercise Price (in dollars per share) |
|
|
|
|
|
|
|
|
|
$ 3.75
|
$ 11.50
|
$ 21.63
|
$ 43.95
|
$ 93.95
|
$ 13.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|